Royalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsen
Novartis’ Phase 3 HORIZON trial for pelacarsen failed to reduce cardiovascular events in the overall study population, Royalty Pharma said Friday. The result removes a major potential royalty-growth catalyst for RPRX, although the filing’s full financial impact and any subgroup findings remain to be established.
Royalty Pharma said Sept. 4 that Novartis' Phase 3 HORIZON outcomes trial for pelacarsen did not meet its primary endpoint. The study tested whether the antisense oligonucleotide could reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and elevated lipoprotein(a), or Lp(a). The endpoint combined cardiovascular death, non-fatal myocardial infarction, non-fatal stroke and urgent coronary revascularization requiring hospitalization.
The result is a setback for a program aimed at a genetically defined cardiovascular-risk population. HORIZON was designed to test the clinical-outcomes benefit of lowering Lp(a), rather than merely demonstrating a change in the biomarker. The principal corporate link is between Novartis, the developer of pelacarsen, and Royalty Pharma, which has an economic interest in approved or commercialized medicines through royalty arrangements. A failed primary endpoint can reduce the probability that a program reaches commercialization or generates the expected royalty stream. RPRX's fiscal-2025 revenue of $2.4B, up 5.1% year over year, with diluted EPS of $1.78 and a 32.4% net margin reflects the company's overall performance.
The topline announcement is not a complete readout of the trial. Key questions remain about whether a subgroup met the endpoint, how safety findings affect the risk profile, and whether Novartis plans additional analysis or development.
The next useful disclosures are the full HORIZON data, including the hazard ratio, confidence interval, statistical significance, subgroup results and safety profile. Investors will also need Novartis' stated development decision and Royalty Pharma's next filing or earnings commentary to determine how the result affects expected cash flows.
Royalty Pharma (RPRX) said Novartis’ Phase 3 HORIZON trial for pelacarsen failed to reduce cardiovascular events in the overall study population.
The immediate issue is cash-flow optionality: a failed primary endpoint lowers the probability that pelacarsen becomes a meaningful royalty asset, while RPRX’s supplied figures do not identify how much of its $2.4B revenue base depends on the program. The read is negative, but the missing treatment-effect, subgroup and accounting details prevent a quantified single-name call until Novartis and Royalty Pharma provide a fuller update.
The trade read is weakened if the full HORIZON dataset shows a clinically meaningful prespecified subgroup, or if Royalty Pharma discloses that pelacarsen has little effect on expected royalty cash flows.
CoverageSource: GlobeNewswire · Published here FRI, SEP 4 · 7:05 PM ET · the only report in this recordHow this is decided →
Earlier context and later coverage are dated relative to this report. Automatically linked reports may cover a broader event.
No later reports linked yet.
Follow this story to find new evidence in your Following desk.
Price context does not establish that the story caused the move.
The strongest bull case is that a prespecified subgroup or favorable full safety and efficacy profile preserves a development path despite the missed overall endpoint, while RPRX’s $2.4B revenue base limits the disclosed exposure.
The bear case is that failure on the composite cardiovascular-event endpoint materially reduces pelacarsen’s commercialization probability and removes a potential growth catalyst from RPRX’s royalty portfolio.
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →